Unknown

Dataset Information

0

Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020.


ABSTRACT: Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR). Data on the performance of the BinaxNOW antigen test compared to rRT-PCR and viral culture by symptom and known exposure status, timing during disease, or exposure period and demographic variables are limited. During 3 to 17 November 2020, we collected paired upper respiratory swab specimens to test for SARS-CoV-2 by rRT-PCR and Abbott BinaxNOW antigen test at two community testing sites in Pima County, Arizona. We administered a questionnaire to capture symptoms, known exposure status, and previous SARS-CoV-2 test results. Specimens positive by either test were analyzed by viral culture. Previously we showed overall BinaxNOW sensitivity was 52.5%. Here, we showed BinaxNOW sensitivity increased to 65.7% among currently symptomatic individuals reporting a known exposure. BinaxNOW sensitivity was lower among participants with a known exposure and previously symptomatic (32.4%) or never symptomatic (47.1%) within 14 days of testing. Sensitivity was 71.1% in participants within a week of symptom onset. In participants with a known exposure, sensitivity was highest 8 to 10 days postexposure (75%). The positive predictive value for recovery of virus in cell culture was 56.7% for BinaxNOW-positive and 35.4% for rRT-PCR-positive specimens. Result reporting time was 2.5 h for BinaxNOW and 26 h for rRT-PCR. Point-of-care antigen tests have a shorter turnaround time than laboratory-based nucleic acid amplification tests, which allows for more rapid identification of infected individuals. Antigen test sensitivity limitations are important to consider when developing a testing program.

SUBMITTER: Almendares O 

PROVIDER: S-EPMC8769733 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020.

Almendares Olivia O   Prince-Guerra Jessica L JL   Nolen Leisha D LD   Gunn Jayleen K L JKL   Dale Ariella P AP   Buono Sean A SA   Deutsch-Feldman Molly M   Suppiah Suganthi S   Hao LiJuan L   Zeng Yan Y   Stevens Valerie A VA   Knipe Kristen K   Pompey Justine J   Atherstone Christine C   Bui David P DP   Powell Tracy T   Tamin Azaibi A   Harcourt Jennifer L JL   Petway Marla M   Bohannon Caitlin C   Folster Jennifer M JM   MacNeil Adam A   Salerno Reynolds R   Kuhnert-Tallman Wendi W   Tate Jacqueline E JE   Thornburg Natalie N   Kirking Hannah L HL   Sheiban Khalilullah K   Kudrna Julie J   Cullen Theresa T   Komatsu Kenneth K KK   Villanueva Julie M JM   Rose Dale A DA   Neatherlin John C JC   Anderson Mark M   Rota Paul A PA   Honein Margaret A MA   Bower William A WA  

Journal of clinical microbiology 20211027 1


Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR). Data on the performance of the BinaxNOW antigen test compared to rRT-PCR and viral culture by symptom and known exposure status, timing during disease, or exposure period and demographic variables are limited. During 3 to 17 November 2020, we collected paired upper respiratory swab specimens to test for SARS-CoV-2 by rRT-PCR and Abbott B  ...[more]

Similar Datasets

| S-EPMC11300111 | biostudies-literature
| S-EPMC1298932 | biostudies-literature
| S-EPMC1065135 | biostudies-literature
| S-EPMC8102632 | biostudies-literature
| S-EPMC87799 | biostudies-literature